Program
triptorelin
Also written as “Triptorelin embonate 22.5 mg”, “Triptorelin (Decapeptyl®)” and “Decapeptyl® SR 22.5mg”.
Its studies are mostly in Prostatic Neoplasms · Puberty, Precocious · Ovarian Hyperstimulation Syndrome, led by 5 companies.
Drug pageTriptorelin: every studyMany companies study it; this page follows only the 20 they lead. All 102 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ipsenits history only | 130 open or running | phase 4since Aug 23, 2012 | Dec 21, 2006 | none ahead |
| Debiopharm | 30 open or running | phase 3since Sep 11, 2008 | Sep 11, 2008 | none ahead |
| Foresee Pharmaceuticalsits history only | 20 open or running | phase 3since Jan 22, 2025 | Jan 22, 2025 | none ahead |
| AbbVieits history only | 10 open or running | phase 4since Jul 9, 2010 | Jul 9, 2010 | none ahead |
| Pharmatechits history only | 10 open or running | phase 4since May 8, 2012 | May 8, 2012 | none ahead |
Also a collaborator on its studies: QPS and Quintiles.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Debiopharm only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 11, 2008First study: phase 3 study in Prostatic NeoplasmsFirst studyNCT00751790 · 120 enrolled · South Africa
- Nov 7, 2011Phase 3 study in Puberty, PrecociousNCT01467882 · 44 enrolled · United States, Chile, Mexico
- Jul 31, 2012Phase 3 study in Prostatic NeoplasmsNCT01656161 · 120 enrolled · South Africa
TargetBeta
“A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH)”NCIt, by rule
“Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Goserelinrule | AstraZeneca | phase 4 | 14 |
Studies
All 3 Debiopharm leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01656161Prostatic Neoplasms · South Africa | 3 | Completed | Aug 2013 | 120 |
| NCT01467882Puberty, Precocious · United States, Chile, Mexico | 3 | Completed | Aug 2013 | 44 |
| NCT00751790Prostatic Neoplasms · South Africa | 3 | Completed | Aug 2007 | 120 |
How it is read
Names in the registry
- “Triptorelin embonate 22.5 mg”, 2 entries
- “Triptorelin (Decapeptyl®)”, 2 entries
- “Decapeptyl® SR 22.5mg”, 1 entry
- “Triptorelin Mesylate”, 1 entry
- “FP-014”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 15 studies
- Puberty, Precocious, 5 studies
- Ovarian Hyperstimulation Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.